Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
QDEL 
Quidel Corporation (QDEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/20/2026: QDEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $34.67
1 Year Target Price $34.67
| 3 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.53B USD | Price to earnings Ratio - | 1Y Target Price 34.67 |
Price to earnings Ratio - | 1Y Target Price 34.67 | ||
Volume (30-day avg) 8 | Beta 0.72 | 52 Weeks Range 19.50 - 42.20 | Updated Date 02/22/2026 |
52 Weeks Range 19.50 - 42.20 | Updated Date 02/22/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -16.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-02-18 | When - | Estimate 0.5134 | Actual 0.46 |
Profitability
Profit Margin -41.46% | Operating Margin (TTM) 4.01% |
Management Effectiveness
Return on Assets (TTM) 1.27% | Return on Equity (TTM) -46.15% |
Valuation
Trailing PE - | Forward PE 9.59 | Enterprise Value 4809061879 | Price to Sales(TTM) 0.56 |
Enterprise Value 4809061879 | Price to Sales(TTM) 0.56 | ||
Enterprise Value to Revenue 1.75 | Enterprise Value to EBITDA 22.78 | Shares Outstanding 67931540 | Shares Floating 63580201 |
Shares Outstanding 67931540 | Shares Floating 63580201 | ||
Percent Insiders 1.08 | Percent Institutions 123.76 |
Upturn AI SWOT
Quidel Corporation
Company Overview
History and Background
Quidel Corporation was founded in 1979 and has evolved into a leading provider of diagnostic solutions. A significant milestone was its merger with Qiagen in 2022, creating a significant player in the diagnostics market. The company has a history of developing and commercializing a wide range of diagnostic tests and instruments.
Core Business Areas
- Infectious Disease Diagnostics: Focuses on rapid diagnostic tests for common infectious diseases such as influenza, Strep A, COVID-19, and respiratory syncytial virus (RSV). These tests are designed for point-of-care settings and physician offices.
- Cardiovascular Disease Diagnostics: Offers diagnostic assays for cardiac markers, aiding in the diagnosis and management of acute myocardial infarction and heart failure.
- Women's Health and Endocrinology: Provides diagnostic tests for pregnancy, ovulation, and various endocrine disorders.
- Specialty Diagnostics: Includes tests for other specific medical conditions and research applications.
Leadership and Structure
QuidelOrtho (post-merger with Qiagen) is led by a management team comprised of experienced executives in the healthcare and diagnostics industries. The organizational structure is designed to support global operations across research and development, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Triage BNP Test: A rapid immunoassay for the quantitative determination of B-type natriuretic peptide (BNP) in whole blood, used to aid in the diagnosis of congestive heart failure. Competitors include Abbott Laboratories (with their ARCHITECT and Alinity platforms) and Roche Diagnostics.
- Sofia 2 Fluorescent Immunoassay Analyzer: A versatile instrument used with various immunoassay test kits for detecting infectious diseases, including influenza and COVID-19. Competitors include Cepheid, Luminex Corporation, and Becton, Dickinson and Company.
- Quidel QuickVue Rapid Tests: A line of rapid diagnostic tests for infectious diseases, including Strep A, influenza, and COVID-19. These are widely used in point-of-care settings. Competitors include Abbott, Meridian Bioscience, and Siemens Healthineers.
Market Dynamics
Industry Overview
The diagnostics industry is characterized by continuous innovation, increasing demand for rapid and accurate testing, and a growing focus on point-of-care solutions. Factors such as the prevalence of infectious diseases, aging populations, and advancements in molecular diagnostics drive market growth. The COVID-19 pandemic significantly accelerated the demand for diagnostic testing, particularly for infectious agents.
Positioning
QuidelOrtho is positioned as a leading provider of immunoassay and molecular diagnostic solutions, with a strong presence in infectious disease testing. Its strengths lie in its broad portfolio of rapid diagnostic tests, its established distribution channels, and its focus on point-of-care applications. The merger with Qiagen further enhances its capabilities in molecular diagnostics.
Total Addressable Market (TAM)
The global in-vitro diagnostics market is a multi-billion dollar market, projected to continue growing at a significant CAGR. QuidelOrtho is well-positioned to capture a substantial portion of this market, particularly in the segments of infectious disease diagnostics and point-of-care testing. The TAM is influenced by factors like disease prevalence, healthcare spending, and technological advancements.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio across multiple diagnostic areas.
- Strong brand recognition in rapid diagnostics.
- Established distribution network and customer base.
- Expertise in immunoassay technology.
- Post-merger synergy with Qiagen's molecular diagnostic capabilities.
Weaknesses
- Dependence on specific product cycles.
- Potential integration challenges post-merger.
- Competition from larger, more diversified healthcare companies.
- Pricing pressures in the diagnostics market.
Opportunities
- Expansion into emerging markets.
- Development of new diagnostic tests for unmet medical needs.
- Leveraging AI and machine learning for diagnostic insights.
- Growth in the point-of-care testing market.
- Further integration of Qiagen's molecular portfolio.
Threats
- Intense competition and price wars.
- Regulatory changes and approval delays.
- Rapid technological advancements by competitors.
- Economic downturns impacting healthcare spending.
- Potential for new infectious disease outbreaks.
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Roche Holding AG (RHHBY)
- Siemens AG (SIEGY)
- Thermo Fisher Scientific Inc. (TMO)
- Danaher Corporation (DHR)
Competitive Landscape
QuidelOrtho competes in a highly competitive market. Its advantages include a strong portfolio of rapid diagnostic tests and a well-established presence in point-of-care. However, it faces competition from larger, more diversified players with broader product offerings and R&D capabilities. The integration with Qiagen aims to strengthen its position, particularly in molecular diagnostics.
Major Acquisitions
Qiagen
- Year: 2022
- Acquisition Price (USD millions): 5900
- Strategic Rationale: To combine Quidel's strength in immunoassay and rapid point-of-care diagnostics with Qiagen's leading position in molecular diagnostics, sample preparation, and bioinformatics, creating a comprehensive diagnostics solutions provider.
Growth Trajectory and Initiatives
Historical Growth: Quidel Corporation has demonstrated growth through product innovation, strategic acquisitions, and expansion into new markets. The COVID-19 pandemic provided a significant, albeit temporary, boost to revenue. The merger with Qiagen represents a pivotal moment for future growth.
Future Projections: Future growth projections for QuidelOrtho are likely to be driven by the integration of Qiagen's complementary diagnostic portfolio, expansion in molecular diagnostics, and continued innovation in point-of-care testing. Analyst estimates would provide specific growth rate expectations.
Recent Initiatives: The most significant recent initiative is the merger with Qiagen, creating a larger and more diversified diagnostics company. Other initiatives likely include ongoing R&D for new diagnostic tests and market expansion efforts.
Summary
QuidelOrtho is a significant player in the diagnostics market, particularly strong in infectious disease testing. The recent merger with Qiagen positions it for substantial growth by integrating complementary capabilities in molecular diagnostics. While facing intense competition and potential integration challenges, the company benefits from growing demand for diagnostic solutions and a diversified product portfolio. Continued innovation and market expansion will be crucial for sustained success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Financial news and analysis websites (e.g., Reuters, Bloomberg, Yahoo Finance)
- Industry research reports
- Company press releases
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Stock market investments are subject to risks, and past performance is not indicative of future results. Investors should conduct their own due diligence or consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quidel Corporation
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 1991-02-01 | President, CEO & Director Mr. Brian J. Blaser | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6600 | Website https://www.quidelortho.com |
Full time employees 6600 | Website https://www.quidelortho.com | ||
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.